HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kahl, B. Articles by Yang, D. Search for Related Content PubMed PubMed Citation Articles by Kahl, B. Articles by Yang, D. Social Bookmarking                   What's this?

Marginal Zone Lymphomas: Management of Nodal, Splenic, and MALT NHL

Correspondence: Brad Kahl, MD, University of Wisconsin School of Medicine and Public Health, Paul P. Carbone Comprehensive Cancer Center, 600 Highland Ave. H4/534 CSC, Madison, WI 53792; e-mail: bsk{at}medicine.wisc.edu.

Abstract

Marginal zone lymphomas are indolent B-cell lymphomas that originate from the marginal zone of B-cell follicles. For several subtypes, the initiation of disease appears to be a consequence of chronic infection and/ or inflammation. While the initial lymphoid hyperplasia is driven by physiologic antigenic stimulation, additional oncogenic events, such as chromosomal translocations leading to constitutive activation of signaling pathways, occur during the progression of disease that ultimately result in antigen-independent lymphoproliferation. Despite having a common origin in the marginal zone of the B-cell follicle, there are distinct clinical and molecular characteristics of marginal zone lymphomas originating at different anatomic sites. As such, marginal zone–derived lymphomas are currently categorized by the World Health Organization (WHO) into those originating in the spleen (splenic marginal zone lymphoma), extranodal mucosa-associated lymphoid tissue (MALT lymphoma), or lymph node (nodal marginal zone lymphoma).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?